Investigational immunotherapy nearly doubles overall survival compared with docetaxel in advanced squamous NSCLC
Patients with metastatic squamous non-small cell lung cancer (NSCLC) whose disease progressed following PD-(L)1 inhibitor therapy experienced a median overall survival of 18.5 months with the investigational anti-CTLA-4 antibody gotistobart, compared with 10.0 months for patients receiving docetaxel, according to updated findings from stage 1 of the Phase III PRESERVE-003 trial.
An investigational anti-CTLA-4 antibody, gotistobart, demonstrated a significant improvement in overall survival compared to docetaxel in patients with metastatic squamous non-small cell lung cancer (NSCLC) whose disease had progressed after PD-(L)1 inhibitor therapy, according to updated results from the Phase III PRESERVE-003 trial.
The median survival was 18.5 months for patients receiving gotistobart, compared to 10.0 months for those who received docetaxel. The risk of death was 43% lower with gotistobart (HR = 0.572), and the drug's safety profile remained consistent with previous reports, showing no new safety signals. The study's lead investigator, Dr. Rama Balaraman, emphasized the potential of gotistobart as a new treatment option for this patient population, supporting further evaluation in the ongoing Phase III trial.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
